2020
DOI: 10.1007/10_2020_138
|View full text |Cite
|
Sign up to set email alerts
|

When Is an In Silico Representation a Digital Twin? A Biopharmaceutical Industry Approach to the Digital Twin Concept

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
22
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 28 publications
(22 citation statements)
references
References 36 publications
0
22
0
Order By: Relevance
“…Digital twins are also being explored by the biopharmaceutical industry [ 28 , 29 ] in an increasing range of applications, e.g., for drug discovery and development. Subramanian describes a digital twin of the liver created by integrating the knowledge and understanding gained about various liver functions, diseases, and the effect of drugs, using a mathematical framework of ordinary differential equations.…”
Section: Digital Twins In Personalised Medicinementioning
confidence: 99%
“…Digital twins are also being explored by the biopharmaceutical industry [ 28 , 29 ] in an increasing range of applications, e.g., for drug discovery and development. Subramanian describes a digital twin of the liver created by integrating the knowledge and understanding gained about various liver functions, diseases, and the effect of drugs, using a mathematical framework of ordinary differential equations.…”
Section: Digital Twins In Personalised Medicinementioning
confidence: 99%
“…The production of therapeutic proteins and vaccine at scale requires manufacturing processes with a very precise control of the final drug quality, that are economically viable and are outstanding in the protection of environment, health, and safety (Lee et al, 2015; Yu & Kopcha, 2017). The development of these processes is extremely time consuming, highly unreliable and costly, since the process design and conditions need to be tailored to the specific characteristics of the product sought to be produced (Portela et al, 2020). Even for “platform processes,” a large number of process design parameters need to be optimized to increase yields and meet product quality specifications (Li et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…The production of therapeutic proteins and vaccine at scale requires manufacturing processes with a very precise control of the final drug quality, that are economically viable and are outstanding in the protection of environment, health and safety [1,2]. The development of these processes is extremely time consuming, highly unreliable and costly, since the process design and conditions need to be tailored to the specific characteristics of the product sought to be produced [3]. Even for "platform processes", a large number of process design parameters need to be optimized to increase yields and meet product quality specifications [4].…”
Section: Introductionmentioning
confidence: 99%